Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update

© The Author(s) 2022 Open Access This article is licensed under a Creative Commons Attri- bution 4.0 International License, which permits use, sharing, adapta- tion, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source...

ver descrição completa

Detalhes bibliográficos
Autor principal: Brannagan, Thomas H. (author)
Outros Autores: Coelho, Teresa (author), Wang, Annabel K. (author), Polydefkis, Michael J. (author), Dyck, Peter J. (author), Berk, John L. (author), Drachman, Brian (author), Gorevic, Peter (author), Whelan, Carol (author), Conceição, isabel (author), Plante-Bordeneuve, Violaine (author), Merlini, Giampaolo (author), Obici, Laura (author), Plana, Josep Maria Campistol (author), Gamez, Josep (author), Kristen, Arnt V. (author), Mazzeo, Anna (author), Gentile, Luca (author), Narayana, Arvind (author), Olugemo, Kemi (author), Aquino, Peter (author), Benson, Merrill D. (author), Gertz, Morie (author)
Formato: article
Idioma:eng
Publicado em: 2022
Assuntos:
Clinical trial
Familial amyloid polyneuropathy
Hereditary transthyretin amyloidosis
Inotersen
Peripheral neuropathies
Polyneuropathy
Texto completo:http://hdl.handle.net/10451/54413
País:Portugal
Oai:oai:repositorio.ul.pt:10451/54413

Texto Completo

http://hdl.handle.net/10451/54413

Registros relacionados